NMRA-511 Phase 1b shows clinically meaningful effect in AD agitation; navacaprant readout in Q2 2026

Neumora Therapeutics, Inc.

NMRA-511 Phase 1b: 15.7-point mean CMAI reduction, no somnolence/sedation; plan higher doses and Phase 2/3 in 2026
Navacaprant KOASTAL-2 and -3 joint readout in Q2 2026; enrollment increased up to 25% beyond original target of 332
NMRA-215 Phase 1 for obesity to initiate H1 2026; weight loss data expected around end of 2026
Cash, cash equivalents and marketable securities support operations into Q3 2027; M4 PAM franchise update mid-2026

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.